Achieving durable responses in patients remains one of the most important challenges for NK cell therapies. This panel will bring together leaders in academia, biotech, and clinical development to discuss strategies for boosting efficacy, extending persistence, and improving the therapeutic potential of NK-based treatments. Experts will explore how next generation engineering, manufacturing, and clinical insights are shaping the future of innate cell therapies.

• Understanding barriers to efficacy and persistence, examining tumor escape, immunosuppression, and NK cell exhaustion that limit clinical outcomes
• Advancing engineering solutions, exploring cytokine support, gene edits, and checkpoint resistance to strengthen NK cell function in vivo
• Improving translation to the clinic, aligning manufacturing, trial design, and biomarker strategies to achieve more consistent and durable responses